Cardiac Sympathetic Denervation in Patients With Refractory Arrhythmic Storm: a Single-center Case Series

January 28, 2026 updated by: Jose Manuel López González

Long-term Outcomes of Ultrasound-guided Percutaneous Bilateral Cardiac Sympathetic Denervation in Patients With Refractory Arrhythmic Storm: a Single-center Case Series

The objective of our study was to evaluate the effectiveness of stellate ganglion block (SGB) and of the bilateral cardiac sympathetic denervation (BCSD) in patients with electrical storm refractory to conventional treatment..

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

A prospective, single-center observational study was designed with the aim of evaluate the safety and short-term efficacy of SGB within the first 24 hours, as well as the long-term effectiveness of ultrasound-guided percutaneous BCSD at 12 months, in patients with refractory electrical storm.

Study Type

Observational

Enrollment (Actual)

18

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Spain
    • Principality of Asturias
      • Oviedo, Principality of Asturias, Spain, 33001
        • FINBA

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

After approval of the study by Principality of Asturias Drug Research Ethics Committee (CEImPA), Spain and obtaining informed consent from the participants, all consecutive patients who underwent SGB followed by BCSD as part of the treatment for refractory electrical storm were included.

Description

Inclusion Criteria:

  • patients over 18 years of age.
  • arrhythmic storm refractory to conventional treatment.

Exclusion Criteria:

  • patients younger than 18 years of age.
  • previous history of heart transplantation.
  • history of previous surgical cardiac sympathetic denervation.
  • patients with neck anatomy considered unsuitable for the procedure (including previous neck surgery, burns, the presence of extensive scars, or large goiters with significant displacement of adjacent structures).
  • contraindications to the interventional technique (such as infection at the puncture site, or refusal to provide consent).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
SGB + BCSD.
Patients with arrhythmic storm refractory to conservative medical treatment undergoing stellate ganglion block (SGB) and bilateral cardiac sympathetic denervation (BCSD) for arrhythmic storm control.
Procedure: Cardiac sympathetic denervation.
Patients underwent stellate ganglion block with 10 ml of levobupivacaine 0.25% and subsequently ultrasound-guided percutaneous bilateral cardiac sympathetic denervation , two neuroablative lesions were created using conventional radiofrequency treatment at 60°C, 20 V for 90 seconds.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Arrhythmic burden.
Time Frame: The arrhythmic burden was assessed both in the early period (first 24 hours following SGB) and in the long term (during the 12 months following BCSD).
The arrhythmic burden was quantified by the number of sustained ventricular arrhythmias, antitachycardia pacing (ATP) therapies, and ICD (implantable cardioverter-defibrillator) shocks recorded during the follow-up period.
The arrhythmic burden was assessed both in the early period (first 24 hours following SGB) and in the long term (during the 12 months following BCSD).

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Jose Manuel López González

Investigators

  • Principal Investigator: Daniel García Iglesias, MD.PhD, Central University Hospital of Asturias, 33001, Spain

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 11, 2023

Primary Completion (Actual)

January 13, 2025

Study Completion (Actual)

December 15, 2025

Study Registration Dates

First Submitted

January 21, 2026

First Submitted That Met QC Criteria

January 21, 2026

First Posted (Actual)

January 29, 2026

Study Record Updates

Last Update Posted (Actual)

January 30, 2026

Last Update Submitted That Met QC Criteria

January 28, 2026

Last Verified

January 1, 2026

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • 2023/139

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Ventricular Arrhythmias

Clinical Trials on Cardiac sympathetic denervation.

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Myanmar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe